Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Anchiano Therapeutics (ANCN) Competitors

Anchiano Therapeutics logo

ANCN vs. WHWK, LITS, SPRB, AADI, ELYM, ATNM, NBRV, EGRX, PYRGF, and LNAI

Should you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Whitehawk Therapeutics (WHWK), Lite Strategy (LITS), Spruce Biosciences (SPRB), Aadi Bioscience (AADI), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), and Lunai Bioworks (LNAI).

Anchiano Therapeutics vs. Its Competitors

Whitehawk Therapeutics (NASDAQ:WHWK) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Whitehawk Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.

In the previous week, Whitehawk Therapeutics had 5 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 5 mentions for Whitehawk Therapeutics and 0 mentions for Anchiano Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.10 beat Anchiano Therapeutics' score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Whitehawk Therapeutics Positive
Anchiano Therapeutics Neutral

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Whitehawk Therapeutics has a net margin of 99.42% compared to Anchiano Therapeutics' net margin of 0.00%. Anchiano Therapeutics' return on equity of 36.08% beat Whitehawk Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Whitehawk Therapeutics99.42% -75.99% -68.57%
Anchiano Therapeutics N/A 36.08%27.40%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Whitehawk Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Anchiano Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Anchiano Therapeutics has lower revenue, but higher earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Whitehawk Therapeutics$25.98M3.66-$63.69M-$0.06-33.67
Anchiano TherapeuticsN/AN/A-$27.12M-$3.46-0.95

Summary

Whitehawk Therapeutics beats Anchiano Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Anchiano Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANCN vs. The Competition

MetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$24.34M$791.93M$6.10B$10.61B
Dividend YieldN/A4.84%5.67%4.71%
P/E Ratio21.871.2985.9726.57
Price / SalesN/A29.90612.14131.72
Price / CashN/A17.6438.5062.09
Price / Book1.637.5412.756.53
Net Income-$27.12M-$7.59M$3.31B$276.43M

Anchiano Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANCN
Anchiano Therapeutics
N/A$3.28
-2.7%
N/A+161.2%$24.34MN/A21.8716
WHWK
Whitehawk Therapeutics
0.9948 of 5 stars
$2.18
-1.8%
N/AN/A$102.74M$25.98M-36.3321News Coverage
Positive News
Analyst Upgrade
LITS
Lite Strategy
N/A$2.39
-2.4%
N/AN/A$85.20M$65.30M-0.50100News Coverage
Analyst Forecast
SPRB
Spruce Biosciences
0.6659 of 5 stars
$144.61
-20.8%
$131.25
-9.2%
+429.6%$80.94M$4.91M-1.6820High Trading Volume
AADI
Aadi Bioscience
N/A$2.22
+3.3%
N/A+9.0%$54.83M$25.07M-0.9740
ELYM
Eliem Therapeutics
N/A$1.81
-8.6%
N/A-65.1%$53.85MN/A-3.429
ATNM
Actinium Pharmaceuticals
1.8658 of 5 stars
$1.56
-1.3%
$4.50
+188.5%
-8.6%$48.67MN/A-1.1230
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59M0.0070
EGRX
Eagle Pharmaceuticals
1.3565 of 5 stars
$3.00
flat
N/A+166.7%$38.96M$257.55M0.00100
PYRGF
PyroGenesis Canada
N/A$0.18
-2.0%
N/A-69.2%$34.36M$9.14M-3.0590Gap Down
High Trading Volume
LNAI
Lunai Bioworks
N/A$1.23
-2.4%
N/AN/A$28.51MN/A-0.1620Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ANCN) was last updated on 10/11/2025 by MarketBeat.com Staff
From Our Partners